Bendamen

Quick links to important sections

Bendamen

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bendamen

Property Description
Active Ingredient Mebendazole
Pharmacological Class Anthelmintic / Benzimidazole derivative
Dosage Form Tablet (including chewable) and Oral Suspension
General Purpose Management of intestinal worm infections
Origin Synthetic

The Identity of Bendamen: An Anthelmintic Benzimidazole

Bendamen is a synthetic medication whose primary component is the active substance Mebendazole, a key agent recognized in the anthelmintic pharmacological class. This classification establishes its specific action against infections caused by parasitic worms. Mebendazole is structurally defined as a benzimidazole derivative, a family of synthetic compounds recognized for their broad-spectrum efficacy against common helminthic infestations. This confirms Bendamen’s focused role in the management of parasitic infection. While the generic substance is widely available, Bendamen often emphasizes the availability of a chewable tablet or a flavored oral suspension, positioning it for treating patient groups, such as children (typically two years and older), who may struggle with swallowing conventional tablets.


Composition and Forms: Oral Tablets and Suspension

The medicinal entity is a single-ingredient product, solely relying on the efficacy of Mebendazole, and is designed for the oral route of administration. The medication is available in distinct dosage forms, typically including the conventional tablet, the chewable tablet, and the liquid oral suspension. The composition is straightforward, combining the necessary quantity of the active substance, Mebendazole, with inert excipients or a suitable liquid vehicle for safe and effective ingestion. Mebendazole functions by disrupting vital processes necessary for parasite survival. This confirms that the drug is chemically designed to be active against the parasites’ cellular processes rather than simply acting as a physical purging agent.


General Purpose: Targeting Intestinal Worm Infections

Bendamen's general therapeutic purpose is the management and clearance of helminthic infections, including those caused by common nematodes like pinworm and roundworm. The drug achieves this by focusing on the parasites’ cellular processes. This specialized function leads to the cessation of essential glucose uptake and subsequent energy deprivation within the parasitic organism. This targeted biochemical action causes the worms to become immobilized and ultimately eliminated from the gastrointestinal tract, resolving the underlying infestation.

Regulatory References

  1. MedlinePlus Mebendazole Drug Information
  2. Mebendazole MedlinePlus Drug Overview

What side effects are possible with Bendamen?

Possible side effects and safety information

The medicine Bendamen (Mebendazole) has an official safety profile categorized by frequency and the body system affected, as documented in regulatory sources [FDA Prescribing Information]. These classifications guide the understanding of how adverse reactions appear in clinical use.

Frequency-Classified Adverse Reactions

The most frequently documented side effects are typically associated with the gastrointestinal system, often linked to the clearance of the parasitic infection itself. The official label categorizes reactions into tiers:

Frequency Category (Regulatory) Example Adverse Reaction(s)
Common Abdominal pain, anorexia (loss of appetite)
Uncommon Diarrhea, flatulence
Rare Neutropenia, reversible liver function disturbances, alopecia, hepatitis

Postmarketing experience also documents reactions with a Frequency Not Known, including severe skin reactions.


Serious Adverse Reactions and Safety Constraints

The label lists specific reactions considered clinically serious. These include severe cutaneous events such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as blood disorders like agranulocytosis and severe neutropenia [EMA SmPC]. These hematologic effects have been primarily associated with use at dosages substantially higher than recommended and for more prolonged durations.

Safety restrictions officially documented include a contraindication for individuals with known hypersensitivity to the active substance. Furthermore, the official label advises that co-administration with metronidazole should be avoided due to the reported risk of severe skin reactions.

Specific regulatory safety notes exist for certain populations: postmarketing reports have noted convulsions in infants below one year of age, and the safety and effectiveness for children under two years of age have not been established.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented overdose profile of Bendamen (Mebendazole), strictly as described in government regulatory documents.

Overdose scope

Feature Official Regulatory Statements
Documented overdose presentations Overdose, including prolonged exposure, may present with evidence of gastrointestinal distress such as abdominal pain, nausea, and vomiting.
Physiological systems affected Systems affected include the Hematopoietic System (neutropenia, agranulocytosis), the Hepatic System (elevated liver enzymes, hepatitis), and the Renal System (glomerulonephritis).
Dose-related or exposure-related factors Risk is associated with high doses or prolonged use substantially exceeding the recommended therapeutic regimen.
Emergency-response statements Seek immediate medical attention for suspected overdose. Contact a Poison Control Center immediately for advice.

Overdose Classifications (High-Level)

Feature Official Regulatory Classification/Statement
Severity classification Risks include manifestations categorized as serious (e.g., hepatitis, agranulocytosis) and requiring intensive monitoring.
Overdose-context constraints No specific antidote is known for Mebendazole overdose; management relies on defined supportive measures.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may lead to severe systemic complications, including agranulocytosis and hepatitis, primarily linked to prolonged, high-dose exposure.
  • Management is defined as symptomatic and supportive treatment, with consideration for procedures such as gastric lavage or activated charcoal if ingestion was recent.
  • Close hospital monitoring is required for assessing hematological and hepatic status following a suspected overdose.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile by listing acute physical signs alongside the potential for severe, delayed organ toxicity affecting the liver, kidneys, and blood cell production. This documented severity dictates that immediate medical attention is required for any suspected overdose to assess the full clinical picture. Since no specific antidote is known, treatment protocols are limited to procedural and supportive care measures, as mandated by official labeling.

Therapeutic Uses of Bendamen

What Bendamen Treats: Main Uses and Benefits

Bendamen (Mebendazole) is an anthelmintic agent generally used to achieve clearance of specific parasitic infestations of the gastrointestinal tract. The medication may be part of symptomatic management and helps ease the overall symptom burden in conditions caused by pinworm, roundworm, hookworm, and whipworm. The application is relevant in conditions involving inflammatory or irritative processes, which contributes to easing the overall symptom load.

Symptom Management and Clinical Contexts

This treatment is applied across domains where additional symptomatic support is needed in conditions presenting with systemic or localized discomfort, including single and mixed parasitic infections. Bendamen is relevant for easing certain distressing symptoms related to physical discomfort, such as Gastrointestinal Distress (stomach pain, nausea) and is commonly used to help with pronounced symptoms such as intense anal itching and subsequent sleeplessness, which may create noticeable physiological strain. The medication is applied in addressing conditions where symptoms may intensify temporarily, and may assist with maintaining functional stability.

Contexts of Family and Recurrent Use

It is commonly used when short-term symptomatic assistance is needed in close-contact patient groups, such as adults and children within the same household, which is relevant in contexts involving heightened systemic burden.


Quick Fact: Supportive Relief for Pinworm Symptoms Bendamen plays a role in managing the frequent and intense anal itching (pruritus ani) and sleep disturbances that are characteristic symptomatic clusters of pinworm infestation, supporting the patient during difficult episodes by easing distress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Contraindications and Eligibility Restrictions

Bendamen (Mebendazole) is an anthelmintic medication generally permitted for use in adults and pediatric patients two years of age and older. Regulatory documents define strict population-based non-eligibility and cautionary use guidelines.

Absolute Non-Eligibility (Contraindicated)

Population Group Restriction Regulatory Basis
Hypersensitivity Contraindicated in patients with a known allergy to mebendazole or its excipients. Official Labeling
Infants Contraindicated in children below the age of 1 year due to reports of convulsions in this age group. Official Labeling
Pregnancy Contraindicated by some European regulatory authorities. U.S. labeling advises caution based on animal data. Official Labeling

Conditional and Cautionary Use

Certain populations are eligible only under conditional use or require increased caution:

  • Pediatric Use: Safety and efficacy have not been established in children younger than two years of age for the standard dose. European guidance recommends that children aged one to two years be treated only when the potential benefit outweighs the potential risk.
  • Organ Function: Use requires caution in patients with impaired hepatic function, as this condition may lead to higher systemic exposure of the drug.
  • Hematologic Issues: Caution is advised for patients with pre-existing bone marrow suppression (e.g., neutropenia or agranulocytosis), especially when using higher doses or for prolonged periods.
  • Lactation: Caution should be exercised when administered to women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interactions documented in official government regulatory documents. These constraints require specific management or avoidance to maintain the drug’s intended safety and efficacy profile.

Pharmacokinetic and Pharmacodynamic Interaction Categories

Interaction Domain Primary Regulatory Constraint
Exposure-Altering Co-medications Required monitoring for toxicity or therapeutic failure.
Pharmacodynamic Risk-Amplifiers Strict warnings or prohibition against combining agents.
Transporter-Interfering Products Defines administration separation rules or avoidance.
Non-Drug Substance Interactions Rules for avoiding specific foods, herbal products, or alcohol.

Officially Documented Interaction Statements

Regulatory agencies note several clinically significant interactions, which are classified based on the mechanism and resulting risk.

  • CYP1A2 Inhibitors: Co-administration with strong inhibitors of the CYP1A2 enzyme (which metabolizes the drug's active components) may lead to increased plasma concentrations of Bendamen, requiring caution and clinical monitoring for signs of heightened toxicity.
  • Allopurinol: Concomitant use with allopurinol has been linked to a significantly increased risk of severe skin toxicity, including life-threatening syndromes such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
  • Myelosuppressive Agents: Co-administration with other agents that cause myelosuppression (bone marrow suppression) may result in additive hematologic toxicity, necessitating close and careful blood count monitoring.
  • Vaccines: Due to the drug's immunosuppressive effects, the immune response to vaccines (both live and inactivated) may be compromised, potentially rendering them ineffective.

Mechanism of Action

Selective Disruption of Helminthic Structure

The mechanism centers on the active substance binding to beta-tubulin, a crucial protein for forming the worm's internal structures called microtubules . The drug selectively inhibits the polymerization of this protein, causing the parasitic cell's structural components, particularly those in the intestinal wall, to disintegrate. This targeted action is due to the significant structural difference between helminthic beta-tubulin and human beta-tubulin.


Cascade of Metabolic Energy Blockade

The loss of microtubules interferes with glucose uptake and transport within the parasite's intestinal cells. By cutting off its primary nutrient source, the drug induces a rapid cascade of energy failure: the worm depletes its stored glycogen reserves and ceases ATP production. This profound metabolic collapse results in the immobilization and death of the helminth, leading to its elimination.


Ovicidal Effect and Mechanism Limitations

The anti-tubulin mechanism also acts on the eggs of susceptible parasitic species, where it inhibits the necessary cell division required for embryonic development, yielding an ovicidal effect. However, the mechanism is constrained by cases of mechanistic resistance, where a genetic mutation in the parasite's beta-tubulin alters its structure, thereby reducing the drug's binding affinity and limiting the functional application of its mechanism.

Dosage and Administration Information

Official Administration of Bendamen (Mebendazole)

Bendamen is prescribed for the oral route of administration and is administered as a short-term, intensive course. The standard protocols define its use across single-dose and divided-dose regimens, independent of meal timing.


Dosage and Schedule Principles

Key Instruction Regimen
Standard Dosing 100 mg single oral dose (Pinworm) or 100 mg twice daily for 3 consecutive days (other infections)
Duration and Re-treatment Short-term course (1 to 3 days). A second course is advised after a three-week interval if not cured
Pediatric Use Same dosage schedule applies to children two years of age and older

Administration Conditions

The medication may be taken without regard to food intake. The tablet forms can be swallowed whole, chewed, or, if ingestion is difficult, crushed and mixed with food or a small amount of water. No special procedures, such as fasting or purging, are required for proper use.

These instructions structure the use of Bendamen as a repeatable intervention, ensuring that proper administration of the course is prioritized over rigid meal timing while stipulating clear requirements for the preparation and ingestion of the available dosage forms.

Recent Clinical Evidence

Research Evidence / Overview of studies for Bendamen

Evidence for Pinworm and Common Roundworm Infections

The primary evidence for Mebendazole was studied for Pinworm (Enterobius vermicularis) and Common Roundworm (Ascaris lumbricoides) in numerous short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These research efforts focus mainly on measuring the Parasitological Cure Rate, which is the clearance of the parasitic organism and its eggs in samples collected after treatment. Studies also tracked related outcomes such as outcomes related to physical discomfort and changes in symptomatic patterns, including pronounced anal itching and outcomes related to sleep disturbance.

In trials studying the clearance of both Pinworm and Roundworm, the research so far indicates a consistent pattern of measured Parasitological Cure Rates and Egg Reduction Rates (ERR), particularly for Roundworm infection. The majority of this evidence was generated from short-term observation periods focusing on short-term clinical endpoints. The overall level of evidence across these indications is noted in the broader evidence landscape.


Evidence for Whipworm and Hookworm Infections

The research that evaluated Mebendazole for Whipworm (Trichuris trichiura) and Hookworm (Necator americanus and Ancylostoma duodenale) was evaluated in short-term RCTs. These studies monitored the Parasitological Cure Rate and the Egg Reduction Rate (ERR) in populations living in endemic areas. For Hookworm and Whipworm, the research highlights changes measured during the study period, but the findings were mixed.

For single-dose regimens, studies reported highly variable Parasitological Cure Rates for Whipworm, and lower measurements of clearance rates for Hookworm. The evidence quality varies across studies, leading to a generally moderate level of evidence classification for these indications. Studies focusing on short-term symptom changes suggest that while egg counts may be notably reduced (ERR), the complete clearance of the parasite (Cure Rate) was observed in some studies to have lower consistency.


What Remains Uncertain in the Research Landscape

While a considerable body of evidence exists, the research highlights areas where certainty remains low or where further data are still emerging. Follow-up durations were limited, typically lasting only 1 to 3 weeks post-treatment, meaning there is limited information for long-term outcomes or the durability of the clearance. Long-term effects are not fully established.

Comparative evidence is lacking for certain dosing patterns, and subgroup findings are uncertain for specific combinations of mixed infections. The findings describe observed group patterns, not personal outcomes.

Key Studies & References

  1. Assessment of Anthelmintic Efficacy of Mebendazole in School Children in Six Countries Where Soil-Transmitted Helminths Are Endemic (Knopp et al. 2012)
  2. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis (Systematic Review, 2013)
  3. Mebendazole - StatPearls (NIH, used for general summary of indications and study types)

Frequently Asked Questions (FAQ)

Common questions about Bendamen (FAQ)


Q: Does Bendamen build up in your system over time?

Studies and official product information indicate that while the drug’s elimination half-life is relatively short (typically 3 to 6 hours), concentrations of the drug and its byproducts may increase with repeated dosing. This means that drug exposure may be higher during a multi-day course compared to a single-dose regimen.


Q: How long does Bendamen stay active in your body after the last dose?

The drug is rapidly processed by the body. According to official regulatory documents, the apparent elimination half-life of the active substance is typically between 3 and 6 hours for most people. This represents the time it takes for half of the dose to be cleared from the system.


Q: Could Bendamen cause weight changes or appetite issues?

Yes, loss of appetite (anorexia) is listed as a commonly reported side effect in official regulatory documents. Additionally, the official label notes that weight loss has been observed as an adverse reaction, though its frequency is not well-established.


Q: Is it normal to feel slightly dizzy or drowsy when first taking Bendamen?

Official postmarketing reports have noted cases of dizziness and drowsiness. While these effects are generally rare or have an unknown incidence, they are recognized in regulatory documents as possible reactions to the medication.


Q: Are there special considerations for taking Bendamen if I have existing kidney problems?

Regulatory documents explicitly advise caution when the drug is administered to patients with impaired hepatic function (liver problems). Though less common, official records of adverse events have included reports of glomerulonephritis (a kidney issue), meaning these issues may necessitate caution or clinical evaluation.


Q: Are there any over-the-counter medicines or supplements that shouldn't be taken with Bendamen?

Official drug interaction summaries state that the use of metronidazole should be avoided due to a reported risk of severe skin reactions. Co-administration with cimetidine may also increase the levels of Bendamen in the body. Regulatory sources advise that all co-medications should be reviewed by a healthcare professional.


Q: Is there a link between Bendamen and headaches or migraines?

Official regulatory documents do not list headache among the most common adverse reactions. However, some sources categorize headache as a rare side effect or one with an an incidence that is not known, based on postmarketing reports.


Q: Is it okay to drive or operate machinery while taking Bendamen?

According to some regulatory authorities, this medicine is not likely to affect your ability to drive or use tools or machinery. However, patients are typically advised to exercise caution if they experience side effects such as dizziness or drowsiness.


Q: How often does a severe allergic reaction occur with Bendamen?

Official labels state that severe allergic reactions, including anaphylaxis, have been observed in postmarketing reports, but a precise frequency is not routinely quantified in clinical studies. Severe skin reactions such as Stevens-Johnson syndrome (SJS) have also been reported.


Q: Is it normal to see a color change in urine or stool while on Bendamen?

While not a common side effect, some adverse event reports have included observations of dark urine and light-colored stools. Patients are advised to note any such changes, as they can sometimes be related to effects on the liver.


Q: What happens if I accidentally take a double dose of Bendamen?

Regulatory documents state that if a dose higher than prescribed is administered, gastrointestinal symptoms such as abdominal cramps, nausea, vomiting, and diarrhea may occur. Taking higher or more prolonged doses than recommended has also been associated with blood and liver disorders.


Q: Are the initial side effects of Bendamen likely to go away after a few weeks?

Some common adverse reactions, such as abdominal pain and diarrhea, are often described in regulatory information as being transient symptoms. These effects may be related to the body's process of clearing the infection and often subside.


Q: What are the general contraindications for taking Bendamen?

Official regulatory documents indicate that Bendamen is contraindicated (must not be used) in two main groups: patients with a known hypersensitivity (allergy) to the drug or its components, and children who are under the age of one year due to reports of convulsions in this young age group.


Q: Do children take the same formulation or dosage of Bendamen as adults?

Official information confirms that the drug is approved for use in children aged two years and older, with a schedule similar to that of adults. The medication is manufactured in different forms, including chewable tablets and liquid suspension, to help with administration.


Q: What should I do if I miss a scheduled dose of Bendamen?

Patient information generally suggests taking the missed dose as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the advice is typically to skip the missed dose and resume the regular schedule.


Q: Can Bendamen affect sleep patterns?

Regulatory documents list drowsiness as a possible adverse reaction, which is a central nervous system effect that could influence sleep. Furthermore, the clinical research for the drug's effectiveness often tracked outcomes related to sleep disturbance.

How should Bendamen be stored and disposed of?

Storage Conditions

Bendamen (mebendazole) must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, tightly closed, and stored away from excess heat, moisture, and direct light; it should not be stored in a bathroom. Freezing the medication is prohibited. Certain formulations must be discarded one month after the container is first opened.

Child-Safety and Disposal

It is an official regulatory requirement that the medicine be kept out of the sight and reach of children and pets. The container's safety cap must be locked, and the product placed in a secure, high location. Unused or expired Bendamen should be disposed of by taking it to a drug take-back program. If a take-back program is unavailable, the product must be mixed with an unappealing substance, sealed in a bag, and then placed in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bendamen found in:

A-Z Index: